EBMT 2023 | Upcoming EU regulations on the manufacturing of ATMPs and their impact on academia
Christian Chabannon, MD, PhD, Paoli-Calmettes Institute, Marseille, France, comments on upcoming updates in the regulations for the manufacturing of advanced therapy medicinal products (ATMPs) in the European Union (EU), including the revision of the EU legislation on tissues and cells, and the efforts of the EBMT to maintain the principle of hospital exemption. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BELLICUM PHARMACEUTICALS: Membership on an entity’s Board of Directors or advisory committees
BMS/CELGENE: Speakers Bureau, Membership on an entity’s Board of Directors or advisory committees
EBMT: Membership on an entity’s Board of Directors or advisory committees
FRESENIUS KABI: Research Funding
KITE/GILEAD: Honoraria, Speakers Bureau, Membership on an entity’s Board of Directors or advisory committees
JANSSEN PHARMACEUTICALS: Membership on an entity’s Board of Directors or advisory committees
JAZZ: Honoraria
MILTENYI BIOTECH: Research Funding
NOVARTIS: Speakers Bureau
SANOFI SA: Speakers Bureau, Honoraria, Research Funding
TERUMO BCT: Speakers Bureau
